BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VM Oncology\, LLC readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies VM Oncology\, LLC's drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03556228-2799@assetmemo.bio
DTSTAMP:20261121T010133Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:VMD-928: Phase 1/2 readout est. (NCT03556228)
DESCRIPTION:VMD-928\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: VMD-9
 28 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexp
 ression Driven Solid Tumors or Lymphoma\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vmd-928#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03556
 228
URL:https://assetmemo.bio/drug/vmd-928#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
